Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 2/20 | 0.56 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.53 |
| ▸ | TLR2 | O60603 | 1/20 | 0.52 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29370367 | 1.00 | KLK7 (0.56) | KLK7KLK5HDAC1HDAC2KMT2A | |
| SCHEMBL29628218 | 1.00 | KLK7 (0.56) | KLK7KLK5HDAC1HDAC2KMT2A | |
| SCHEMBL29521232 | 0.95 | KLK7 (0.54) | KLK7KLK5HDAC1HDAC2KMT2A | |
| SCHEMBL30501605 | 0.94 | HDAC1 (0.50) | KLK7KLK5HDAC1HDAC2KMT2A | |
| SCHEMBL2289677 | 0.93 | KLK7 (0.54) | KLK7KLK5HDAC1HDAC2KMT2A | |
| SCHEMBL31011377 | 0.93 | KLK7 (0.54) | KLK7KLK5HDAC1HDAC2KMT2A | |
| SCHEMBL30631751 | 0.93 | KLK7 (0.54) | KLK7KLK5HDAC1HDAC2KMT2A | |
| SCHEMBL14064950 | 0.93 | KLK7 (0.54) | KLK7KLK5HDAC1HDAC2KMT2A | |
| SCHEMBL2289683 | 0.93 | KLK7 (0.54) | KLK7KLK5HDAC1HDAC2KMT2A | |
| SCHEMBL31488205 | 0.93 | KLK7 (0.49) | KLK7KLK5HDAC1HDAC2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160213742-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160213742-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160213742-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | FPR1, FPR3, FPR2 | KLK7 1804/4885KLK5 2284/4885HDAC1 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.